A Multi-center, Primary Care-Based, Open-Label Study to Assess the Success of Converting Opioid-Experienced Patients, With Chronic, Moderate to Severe Pain, to EMBEDA Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse, and Diversion.
Phase of Trial: Phase IV
Latest Information Update: 04 Sep 2012
At a glance
- Drugs Morphine; Naltrexone
- Indications Pain
- Focus Therapeutic Use
- Acronyms ConvERT
- Sponsors Alpharma
- 04 Sep 2012 Actual patient number changed from 679 to 684 as reported by ClinicalTrials.gov record.
- 22 Sep 2011 Company added as trial sponsor as reported by ClinicalTrials.gov.
- 04 Apr 2011 Planned end date changed from 1 Jan 2012 to 1 Apr 2011 as reported by ClinicalTrials.gov.